SEC Form 4 · accession 0001209191-16-137391
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Abhay Joshi
Officer — Chief Operating Officer
Period of report
Aug 12, 2016
Accepted (ET)
Aug 16, 2016 · 8:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 12, 2016 | M | 666 | $6.60 | A | 35,041 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F1 | $6.60 | Aug 12, 2016 | M | 666 | D | — | Sep 18, 2016 | Common Stock | 666 | 0 | D |
Explanation of responses
- F1The option is fully vested.